Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Neuroimmunol. 2012 Oct 15;251(1-2):80-6. doi: 10.1016/j.jneuroim.2012.06.008. Epub 2012 Jul 6.

Cerebrospinal hepatocyte growth factor levels correlate negatively with disease activity in multiple sclerosis.

Author information

  • 1Multiple Sclerosis Research Center of New York, 521 W 57th Street, 4th floor, New York, NY 10019, USA.

Abstract

The hepatocyte growth factor (HGF) is a pleiotropic cytokine with neuroprotective and anti-inflammatory properties. Additionally, it enhances axonal outgrowth and oligodendroglial maturation. We studied the expression of HGF by cells derived from cerebrospinal fluid (CSF), quantified HGF in CSF samples and investigated the glial expression of HGF in vitro. We found decreased expression of HGF in CSF cells as well as reduced CSF but not plasma HGF protein levels in MS. MS patients with active disease had lower HGF CSF levels than inactive MS patients, and treatment with Natalizumab correlated with increased CSF concentration of HGF. In vitro, glial production of HGF was reduced by CSF from MS patients in comparison with CSF from controls. CSF levels of CCL2, a known inducer of HGF, also correlated strongly with HGF levels. We conclude that the expression of HGF within the CNS is reflective of disease activity in MS and this may be due to decreased induction of HGF by CCL2. Furthermore, the decreased HGF associated with active disease may potentially contribute to reduced stimulation for remyelination and the occurrence of shadow plaques frequently seen in MS patients. Our results merit further validation to establish whether CSF HGF is a biomarker for MS disease activity.

Copyright © 2012 Elsevier B.V. All rights reserved.

PMID:
22771249
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk